S. Day

发表

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Chun Xing Li, R. Young, S. Charleson, 2005, Bioorganic & medicinal chemistry letters.

Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes.

M. D'antoni, S. Day, N. Chauret, 2004 .

Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.

Chun Xing Li, J. Yergey, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

Protocols of in vitro protein covalent binding studies in liver.

S. Day, Jean-François Lévesque, Allen N. Jones, 2011, Methods in molecular biology.

Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes.

M. D'antoni, S. Day, N. Chauret, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitor.

Y. Leblanc, J. Yergey, J. Silva, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry.

M. Ouellet, K. Bateman, Jennifer L Baker, 2004, Chemical research in toxicology.

High-Throughput Agonist Shift Assay Development for the Analysis of M1-Positive Allosteric Modulators

Michael F. Finley, J. Hermes, V. Uebele, 2017, SLAS discovery : advancing life sciences R & D.

Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.

D. Denis, Y. Leblanc, G. O'neill, 2008, Bioorganic & medicinal chemistry letters.

Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.

R. Young, J. Mancini, D. Nicholson, 2009, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.

R. Young, J. Mancini, H. Perrier, 2008, Bioorganic & medicinal chemistry letters.

Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.

Chun Xing Li, J. Yergey, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.

R. Young, R. Zamboni, Y. Aubin, 2007, Bioorganic & medicinal chemistry letters.

Pharmacokinetics and Metabolism in Rats, Dogs, and Monkeys of the Cathepsin K Inhibitor Odanacatib: Demethylation of a Methylsulfonyl Moiety as a Major Metabolic Pathway

K. Koeplinger, I. Mcintosh, K. Kassahun, 2011, Drug Metabolism and Disposition.

A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds.

Jean-François Truchon, Christopher I Bayly, C. Bayly, 2007, Bioorganic & medicinal chemistry letters.

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

R. Young, D. Denis, S. Kargman, 2007, Journal of medicinal chemistry.

Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560.

H. Perrier, K. Bateman, Y. Girard, 2006, Journal of mass spectrometry : JMS.

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.

R. Young, J. Mancini, R. Friesen, 2010, Bioorganic & medicinal chemistry letters.

Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.

R. Young, R. Zamboni, K. Bateman, 2007, Bioorganic & medicinal chemistry letters.

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.

R. Young, J. Mancini, R. Friesen, 2010, Bioorganic & medicinal chemistry letters.